NEW YORK, May 13, 2021 /CNW/ — MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development. As MindMed progresses it’s Discover and Develop efforts for multiple commercial clinical programs including LSD and an ibogaine derivative, 18-MC, Peter will lead MindMed’s product development…


Previous articleIntelGenx Announces Shareholder Approval of atai Investment
Next articleCOMPASS Pathways plc announces financial results and business highlights for the first quarter 2021